Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results 

Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2024 full-year financial results on Thursday, March 27, 2025.

Inventiva’s 2024 full-year financial results will be published on Wednesday, March 26, 2025  at 4:00 pm (New York), 9:00 pm (Paris).

Frédéric Cren, CEO and cofounder of Inventiva and Jean Volatier, Chief Financial Officer of Inventiva will hold a conference call in English, followed by a Q&A session, on Thursday, March 27, 2025,  at 8:00 am (New York), 1:00 pm (Paris). 

The conference call and the slides of the presentation will be webcast live here. 

In order to receive the conference access information necessary to join the conference call, it is required to register in advancehere. Participants will need to use the conference access information provided in the e-mail received at the point of registering (dial-in number and access code).

A replay of the conference call and the presentation will be available after the event on our website.

About Inventiva  

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility. 

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the NASDAQ Global Market in the United States (ticker: IVA).www.inventivapharma.com

Contacts 

Inventiva

Pascaline Clerc

EVP, Strategy and Corporate Affairs media@inventivapharma.com +1 202 499 8937

Brunswick Group

Tristan Roquet Montegon

Aude Lepreux 

Julia Cailleteau Media relations inventiva@brunswickgroup.com

+33 1 53 96 83 83

1

ICR Healthcare

Patricia L. Bank

Investor relations     patti.bank@icrhealthcare.com   

   +1 415 513 1284